RxDoctor Payments Data

Ketheeswaran Kathiripillai, MD

Internal Medicine · Temple Terrace, FLNPI 1972549368

Payments from drug & device makers

$815in general payments, 2019–2025

Across 11 payments — averaging $74.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$418
  • Ironwood Pharmaceuticals, Inc$199
  • GSK$130
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20
  • AstraZeneca$19
  • Johnson & Johnson$18
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$815 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$182,478
Medicare patients
969
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,214$286,681
TrulicityDulaglutide65$50,294
JanuviaSitagliptin Phosphate158$40,066
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog311$39,460
ErtapenemErtapenem Sodium96$35,684
NuplazidPimavanserin Tartrate16$33,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$25,008
JardianceEmpagliflozin103$24,318
Divalproex Sodium258$22,581
EntrestoSacubitril/Valsartan86$21,544
MyrbetriqMirabegron103$21,451
Mirtazapine476$20,979
ProcritEpoetin Alfa16$20,727
XareltoRivaroxaban71$20,443
Gabapentin860$19,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonProcrit, Xarelto$18$41,16987 claims
GSKTrelegy Ellipta, Breo Ellipta$130$35,02767 claims
AstraZenecaFarxiga, Lokelma$19$27,49395 claims
NovartisEntresto$12$21,54486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Temple Terrace

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →